Today, Irene Gabashvili, PhD., MEBO Research Scientific Director and Principal Investigator of the MEBO Clinical Trial, "Microbial Basis of Systemic Malodor and PATM Conditions (PATM), NCT03582826(2018-2020), published a paper on the findings of this study in the JMIR Dermatology Publications.
Dr. Gabashvili discusses her finding in her Aurametrix site, Olfactics and Olfactory Diagnostics: New Paper Reveals Insights into Bacteria that Live...: What do MEBO (metabolic body odor), PATM ("People are Allergic to ME" condition) and TMAU (trimethylaminuria) have in common...
Irene gives us the following page in her Aurametrix Blog, which shows the last 3-4 digits of MEBO participants' IDs. This way they can recognize themselves in the "vector field" of results. These 22 participants had at least one pair of "better" and "worse" MEBO/PATM symptoms. The paper has more figures with results of the remaining participants, analyzed in several different ways.
Quotes from the paper:
Conclusions: ...Our work paves the way for the development of cost-effective diagnostics of MEBO and PATM conditions based on an at-home stool test...
Another implication of this work is that individuals with a high abundance of cutaneous malodor bacteria in the gut might benefit from reducing levels of these bacteria. We note that one of the common causes of both halitosis and axillar odor is a zinc deficiency. Zinc oxide is known to decrease populations of bacteria discussed in this work when applied externally [41], attenuating self-perceived malodor. Zinc also contributes to the reduction of halitosis [42]. However, not all people with MEBO and PATM are zinc deficient, and it is important to retain certain levels of cutaneous odor-producing bacteria in the body, as they prevent some skin, ear, and respiratory infections
Gabashvili IS
Cutaneous Bacteria in the Gut Microbiome
as Biomarkers of Systemic Malodor
and People Are Allergic to Me (PATM) Conditions:
Insights From a Virtually Conducted Clinical Trial
Trial Registration:ClinicalTrials.gov NCT03582826
International Registered Report Identifier
(IRRID):RR2-10.1101/2020.08.21.20179242
0 comments: